Evidence Snapshot
What this grade covers
Applies to Lypressin's direct human clinical evidence: one original-era open-label clinical series establishing effective antidiuretic control in diabetes insipidus (PMID 14200290, N=13), one very small allergy-alternative case series (PMID 5694174, N=3), and one genuine comparative human study directly testing LVP against Desmopressin for a specific (memory) endpoint (PMID 7178372). This is real historical clinical evidence, not an absence of evidence, but it is genuinely sparse by modern standards: no randomized controlled trial of Lypressin itself was identified, sample sizes are very small, and the evidence base is entirely 1960s-1980s era with no modern replication. This low grade reflects DATA SPARSITY AND AGE, not a safety failure — no source in this manifest attributes any serious adverse outcome to Lypressin itself, and Lypressin's US discontinuation is independently and directly confirmed as commercial, not safety-driven. This contrast (low grade due to sparsity, not due to a documented safety failure) is distinct from Ornipressin's low-moderate grade, which is safety-failure-informed.
Regulatory Context
Lypressin (Diapid) was FDA-approved historically for central diabetes insipidus and was withdrawn from the US market in 2000 at the sponsor's own request because it was no longer being marketed — a commercial, not safety-driven, withdrawal (21 CFR 314.150(c) 'no longer marketed' category). No current US or other major-regulator marketing status was identified in this review.
Research Takeaway
Lypressin is the synthetic pharmaceutical form of lysine vasopressin (LVP), the natural posterior-pituitary vasopressin sequence of the domestic pig, differing from human Arginine Vasopressin by a single residue (lysine instead of arginine) at position 8; it is a distinct sequence variant, not an alias, of human AVP.
See all 6 evidence claims →Quick Summary
Lypressin is the synthetic pharmaceutical form of lysine vasopressin, the natural pig vasopressin sequence, historically marketed in the US as Diapid for central diabetes insipidus. Its strongest evidence is a small original-era clinical series showing effective antidiuretic control, and its major limitation is a genuinely sparse, dated human evidence base with no randomized controlled trial — a limitation of evidence volume and age, not a documented safety failure, and distinct from its purely commercial (not safety-driven) US market withdrawal in 2000.
Mechanism & Research Overview
Lypressin is the synthetic pharmaceutical form of lysine vasopressin, the natural pig vasopressin sequence, historically marketed in the US as Diapid for central diabetes insipidus. Its strongest evidence is a small original-era clinical series showing effective antidiuretic control, and its major limitation is a genuinely sparse, dated human evidence base with no randomized controlled trial — a limitation of evidence volume and age, not a documented safety failure, and distinct from its purely commercial (not safety-driven) US market withdrawal in 2000.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Lypressin is the synthetic pharmaceutical form of lysine vasopressin (LVP), the natural posterior-pituitary vasopressin sequence of the domestic pig, differing from human Arginine Vasopressin by a single residue (lysine instead of arginine) at position 8; it is a distinct sequence variant, not an alias, of human AVP.
Sources: NCATS Inxight Drugs: Lypressin Substance Record
Supported
In an original open-label clinical series, synthetic lysine vasopressin (Lypressin) nasal spray effectively controlled central diabetes insipidus in the majority of patients studied, with only mild, non-serious adverse effects (nasal irritation; increased bowel frequency in one case).
Sources: Synthetic lysine vasopressin nasal spray in the treatment of diabetes insipidus
Supported
Lypressin nasal spray has been used clinically as an alternative antidiuretic treatment for diabetes insipidus patients who developed allergic reactions to older, animal-origin vasopressin preparations.
Does not establish
Evidence boundary: Based on a very small (N=3), uncontrolled case series; not generalizable as a formal allergy-substitution protocol.
Supported
Direct Lypressin/lysine-vasopressin human clinical evidence is sparse by modern standards, with no randomized controlled trial identified; Lypressin was largely superseded clinically by desmopressin, which has a longer duration of action, greater V2 selectivity, and a much larger modern clinical-trial evidence base (see the separate Desmopressin page).
Supported
Diapid (Lypressin Nasal Solution USP) was withdrawn from the US market in 2000 at the sponsor's own request because it was no longer being marketed, per the Federal Register notice itself; the notice contains no mention of any safety or effectiveness concern.
Supported
Lypressin's low evidence grade and its commercial discontinuation must not be confused with a safety failure; no source in this review attributes a serious adverse outcome to Lypressin itself, in direct contrast to Ornipressin's independently documented, safety-driven abandonment in hepatorenal-syndrome treatment (see the separate Ornipressin page).
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
No randomized controlled trial of Lypressin was identified; evidence is small, open-label, and 1960s-1980s era.Safety Consideration
Materially shorter duration of action and lower V2-selectivity than Desmopressin, per direct comparative literature; this is a pharmacological limitation, not a documented safety failure.Safety Consideration
Risk of conflating 'lysine vasopressin' (the natural porcine hormone) with 'Lypressin' (the synthetic drug form) or with human AVP; each is a distinct entity and must be kept terminologically separate in any implementation.Safety Consideration
The Federal Register withdrawal notice explicitly documents a 'no longer marketed' commercial withdrawal, with no safety or effectiveness language anywhere in the notice.
Research Areas Being Studied
Research areas discussed on this page reflect the Renal / Fluid-Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients (1982):
- Lypressin nasal spray. Usefulness in patients who manifest allergies to other antidiuretic hormone preparations (1968):
- Synthetic lysine vasopressin nasal spray in the treatment of diabetes insipidus (1964):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients | 1982 | A single intramuscular injection or sub-chronic intranasal lysine-vasopressin (LVP) or DDAVP normalized disturbed memory function in diabetes insipidus patients and improved memory in healthy individuals — a genuine head-to-head direct comparison of LVP against Desmopressin in the same study. | |||
| Lypressin nasal spray. Usefulness in patients who manifest allergies to other antidiuretic hormone preparations | 1968 | N=3 diabetes insipidus patients with allergic reactions (skin eruption; marked tenesmus/constipation) to animal-origin vasopressin tannate-in-oil preparations | Lypressin nasal spray was tolerated as an antidiuretic alternative in these allergy cases. | ||
| Synthetic lysine vasopressin nasal spray in the treatment of diabetes insipidus | 1964 | N=13 diabetes insipidus patients | Synthetic lysine vasopressin nasal spray (35-125 units/day, 3-5 doses/day) satisfactorily and conveniently controlled diabetes insipidus. | Minor nasal irritation in 3 patients; increased bowel-movement frequency in 1 child at a higher dose — mild, non-serious adverse effects, not an ischemic or systemic safety signal. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Diapid (Lypressin Nasal Solution USP) Nasal Spray; Withdrawal of Approval of a New Drug Application — Federal Register Notice | 2000 | Diapid (Lypressin Nasal Solution USP), NDA 16-755, applicant Novartis Pharmaceuticals Corp. Withdrawal notice issued March 7, 2000, effective April 19, 2000, quoted verbatim: 'the drug products were no longer marketed and requested that the approval of the applications be withdrawn.' | The notice contains no mention of safety or effectiveness concerns anywhere in its text; withdrawal is the standard 21 CFR 314.150(c) 'no longer marketed' administrative category, not a safety-driven withdrawal. | No source link available | |
| NCATS Inxight Drugs: Lypressin Substance Record | Confirms Lypressin as the synthetic pharmaceutical form of lysine vasopressin (LVP), the natural posterior-pituitary vasopressin sequence of the domestic pig, differing from human Arginine Vasopressin by one residue (lysine instead of arginine) at position 8. | No source link available |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Lypressin (Diapid) and other drugs for diabetes insipidus | 1972 | Discovery/context-tier review of Lypressin and other diabetes-insipidus drugs; no abstract available in PubMed's own record. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published historical clinical research and official regulatory history about Lypressin and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Lypressin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.